
Instil Bio (TIL) Stock Forecast & Price Target
Instil Bio (TIL) Analyst Ratings
Bulls say
Instil Bio Inc's stock showed a significant rebound with a nearly 500% increase following the full HARMONi-2 dataset disclosure, indicating strong market confidence in its tumor infiltrating lymphocyte (TIL) therapies. The company's unique CoStAR platform for genetically engineered TIL therapies opens pathways to treat various solid tumors, enhancing its competitive edge within the biopharmaceutical landscape. Furthermore, a discounted cash flow analysis estimated the firm's value at approximately $884 million, reflecting the potential for substantial growth driven by ongoing research and favorable developments in the industry.
Bears say
Instil Bio reported a net loss of $1.82 for the fourth quarter of 2024, contributing to a projected full-year net loss of $11.51 per share for 2025, a significant increase from the previously estimated loss of $3.65 per share. Key risks impacting the company's outlook include potential delays in the clinical development of its therapies, particularly related to the performance of candidate AXN-2510 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), as well as the possibility of future dilution. These factors collectively cast a negative outlook on Instil Bio’s financial stability and performance trajectory.
This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.
Instil Bio (TIL) Analyst Forecast & Price Prediction
Start investing in Instil Bio (TIL)
Order type
Buy in
Order amount
Est. shares
0 shares